Details for Patent: 7,619,007

Title:	Method and composition for administering an NMDA receptor antagonist to a subject
Abstract:	The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
Inventor(s):	Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA), Meyerson; Laurence R. (Las Vegas, NV)
Assignee:	Adamas Pharmaceuticals, Inc. (Emeryville, CA)
Filing Date:	Nov 22, 2005
Application Number:	11/285,905
Claims:	1. A method of administering memantine to a human subject in need thereof, comprising 10-100 mg of: orally administering to the human subject once per day over multiple days a sustained release oral dosage form comprising memantine or a pharmaceutically acceptable salt thereof and a component that sustains release of the memantine or salt thereof, wherein a therapeutically effective daily dose of the memantine or salt thereof is administered from initiation of therapy without prior dose escalation of memantine, and wherein the subject has a condition selected from the group consisting of Alzheimer's disease, dementia, Parkinson's disease, and neuropathic pain. 2. The method of claim 1, wherein the sustained release component comprises a sustained release coating. 3. The method of claim 1, wherein the sustained release component comprises a sustained release matrix. 4. The method of claim 1, wherein the sustained release component comprises a sustained release coating and a sustained release matrix. 5. The method of claim 1, wherein the sustained release oral dosage form further comprises a delayed release component. 6. The method of claim 1, wherein the dosage form comprises a capsule or a tablet. 7. The method of claim 1, wherein the condition is dementia. 8. The method of claim 7, wherein the dementia is Alzheimer's disease dementia. 9. The method of claim 1, wherein the dosage form comprises 10-50 mg of memantine or salt thereof. 10. The method of claim 1, wherein the dosage form comprises at least 22.5 mg of memantine or salt thereof 11. In a method of avoiding side-effects in a human subject initiating memantine therapy, the improvement comprising orally administering to the subject once per day over multiple days a sustained release oral dosage form comprising 10-100 mg of memantine or a pharmaceutically acceptable salt thereof and a component that sustains release of the memantine or salt thereof, wherein a therapeutically effective daily dose of the memantine or salt thereof is administered from initiation of therapy without prior dose escalation of memantine, and wherein the subject has a condition selected from the group consisting of Alzheimer's disease, dementia, Parkinson's disease, and neuropathic pain. 12. The method of claim 11, wherein the sustained release component comprises a sustained release coating. 13. The method of claim 11, wherein the sustained release component comprises a sustained release matrix. 14. The method of claim 11, wherein the sustained release component comprises a sustained release coating and a sustained release matrix. 15. The method of claim 11, wherein the sustained release oral dosage form further comprises a delayed release component. 16. The method of claim 11, wherein the dosage form comprises a capsule or a tablet. 17. The method of claim 11, wherein the condition is dementia. 18. The method of claim 17, wherein the dementia is Alzheimer's disease dementia. 19. The method of claim 11, wherein the dosage form comprises 10-50 mg of memantine or salt thereof. 20. The method of claim 11, wherein the dosage form comprises at least 22.5 mg of memantine or salt thereof.